Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug shows promise in shrinking breast cancer tumors before surgery

NCT ID NCT04191382

Terminated Disease control Sponsor: Sanofi Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated May 23, 2026 · Updated 25 times

Summary

This study tested a new hormone therapy, amcenestrant, at two different doses against the standard drug letrozole in postmenopausal women with a common type of early breast cancer (ER+/HER2-). The goal was to see if amcenestrant could better slow tumor growth before surgery. The study was stopped early, and results are not yet conclusive.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Investigational Site Number 0560001

    Leuven, 3000, Belgium

  • Investigational Site Number 0560002

    Namur, 5000, Belgium

  • Investigational Site Number 2500001

    Nantes, 44093, France

  • Investigational Site Number 2500002

    Saint-Cloud, 92210, France

  • Investigational Site Number 2500003

    Toulouse, 31059, France

  • Investigational Site Number 2500004

    Paris, 75010, France

  • Investigational Site Number 3800001

    Milan, 20141, Italy

  • Investigational Site Number 3800002

    Milan, 20132, Italy

  • Investigational Site Number 3800004

    Meldola, 47014, Italy

  • Investigational Site Number 3920001

    Yokohama, Japan

  • Investigational Site Number 3920002

    Osaka, Japan

  • Investigational Site Number 3920003

    Sapporo, Japan

  • Investigational Site Number 6430002

    Saint Petersburg, 197758, Russia

  • Investigational Site Number 6430003

    Saint Petersburg, 194156, Russia

  • Investigational Site Number 6430004

    Moscow, 119991, Russia

  • Investigational Site Number 6430006

    Moscow, 117186, Russia

  • Investigational Site Number 6430007

    Saint Petersburg, 195271, Russia

  • Investigational Site Number 7240001

    Madrid, 28041, Spain

  • Investigational Site Number 7240002

    Valencia, 46010, Spain

  • Investigational Site Number 7240003

    Córdoba, 14004, Spain

  • Investigational Site Number 7240005

    Barcelona, 08003, Spain

  • Investigational Site Number 8040001

    Uzhhorod, 88000, Ukraine

  • Investigational Site Number 8040002

    Vinnytsia, 21029, Ukraine

  • Investigational Site Number 8040004

    Kharkiv, 61166, Ukraine

  • Investigational Site Number 8040005

    Zaporizhzhya, 69040, Ukraine

  • Investigational Site Number 8400005

    Lincoln, Nebraska, 68506, United States

  • Investigational Site Number 8400007

    Hato Rey, 00917, Puerto Rico

  • Investigational Site Number 8400010

    Los Angeles, California, 90095, United States

  • Investigational Site Number 8400012

    Tacoma, Washington, 98405, United States

  • Investigational Site Number 8400014

    Tucson, Arizona, 85724, United States

  • Investigational Site Number 8400016

    Winston-Salem, North Carolina, 27157, United States

  • Investigational Site Number 8400018

    Fort Wayne, Indiana, 46804, United States

Conditions

Explore the condition pages connected to this study.

BREAST CANCER